better antibody



05.18.16: Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS


FierceBiotech: Xencor spotlighted as one of 10 Next-Gen Biologics Platforms

Xencor 2016 Annual Stockholders Meeting: June 23, 2016 1:30 PM PST

The offices of Cooley LLP — 4401 Eastgate Mall, San Diego, CA 92121

Xencor's CEO speaks to BioWorld about XmAb5871, XmAb7195 for asthma, its IPO and partnering in China. View »


Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life.

Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners.

Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.